Arcturus Therapeutics Holdings Inc. Given Consensus Recommendation of Buy by Brokerages

ARCT Stock  USD 18.34  0.83  4.74%   
Slightly above 70 percent of all Arcturus Therapeutics' private investors are curious in acquiring. The analysis of the overall investor sentiment regarding Arcturus Therapeutics Holdings suggests that a large number of traders are confidant. Arcturus Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Arcturus Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Arcturus Therapeutics Holdings Inc. has been assigned a consensus recommendation of Buy from the eight analysts that are covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price

Read at thelincolnianonline.com
news
  

Arcturus Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Arcturus Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Arcturus Therapeutics Fundamental Analysis

We analyze Arcturus Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcturus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcturus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Retained Earnings

Retained Earnings Comparative Analysis

Arcturus Therapeutics is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.

Arcturus Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Arcturus Therapeutics stock to make a market-neutral strategy. Peer analysis of Arcturus Therapeutics could also be used in its relative valuation, which is a method of valuing Arcturus Therapeutics by comparing valuation metrics with similar companies.

Peers

Arcturus Therapeutics Related Equities

FATEFate Therapeutics   18.28   
0%
100.0%
GOSSGossamer Bio   6.06   
0%
33.0%
BMEABiomea Fusion   3.13   
0%
17.0%
BDTXBlack Diamond   3.11   
0%
17.0%
NTLAIntellia Therapeutics   2.70   
0%
14.0%
PLRXPliant Therapeutics   2.00   
0%
10.0%
STOKStoke Therapeutics   1.68   
0%
9.0%
DAWNDay One   1.53   
0%
8.0%
BPMCBlueprint Medicines   1.35   
0%
7.0%
CRSPCrispr Therapeutics   0.65   
0%
3.0%
BEAMBeam Therapeutics   0.63   
0%
3.0%
AKROAkero Therapeutics   0.22   
1.0%
0%
FDMT4D Molecular   0.38   
2.0%
0%
CRBUCaribou Biosciences   0.45   
2.0%
0%
MDGLMadrigal Pharmaceuticals   0.98   
5.0%
0%
ACLXArcellx   1.12   
6.0%
0%
ETNB89bio   1.64   
8.0%
0%
AMLXAmylyx Pharmaceuticals   3.48   
19.0%
0%

Additional Tools for Arcturus Stock Analysis

When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.